BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) + CT Receive Health Canada Approval for Metastatic Non-Small Cell Lung Cancer

August 12, 2020 Auto Bot approval, BMS, CT, Health Canada, ipilimumab, Metastatic, Nivolumab, Non-Small Cell Lung Cancer, Opdivo, Receive, regulatory, Yervoy 0

Shots:

  • The approval is based on P-III CheckMate -9LA study assessing Opdivo + Yervoy combined with two cycles of platinum-doublet CT vs CT (four cycles followed by optional pemetrexed maintenance therapy if eligible) as a 1L treatment in patients with metastatic/ recurrent NSCLC regardless of PD-L1 expression and histology
  • The study met its 1EPs & 2EPS, demonstrating OS, PFS, and ORR for the dual immunotherapy. @12.7mos. follow up mOS (15.6 mos. vs 10.9 mos.)
  • The approval marks the availability of the first dual immuno-oncology in NSCLC treatment in Canada

Click here ­to­ read full press release/ article | Ref: BMS | Image: BMS